Laddar...
PARP inhibition — not all gene mutations are created equal
Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improve...
Sparad:
| I publikationen: | Nat Rev Urol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7959484/ https://ncbi.nlm.nih.gov/pubmed/30498248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41585-018-0129-3 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|